Deborah A Lannigan

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

1. Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101. Li M, Li Y, Mrozowski RM, Sandusky ZM, Shan M, Song X, Wu B, Zhang Q, Lannigan DA, O'Doherty GA (2015) ACS Med Chem Lett 6(1): 95-9
   › Primary publication · 25589938 (PubMed) · PMC4291707 (PubMed Central)
2. De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101. Mrozowski RM, Sandusky ZM, Vemula R, Wu B, Zhang Q, Lannigan DA, O'Doherty GA (2014) Org Lett 16(22): 5996-9
   › Primary publication · 25372628 (PubMed) · PMC4251525 (PubMed Central)
3. Improving the affinity of SL0101 for RSK using structure-based design. Mrozowski RM, Vemula R, Wu B, Zhang Q, Schroeder BR, Hilinski MK, Clark DE, Hecht SM, O'Doherty GA, Lannigan DA (2012) ACS Med Chem Lett 4(2): 175-179
   › Primary publication · 23519677 (PubMed) · PMC3601785 (PubMed Central)
4. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor. Utepbergenov D, Derewenda U, Olekhnovich N, Szukalska G, Banerjee B, Hilinski MK, Lannigan DA, Stukenberg PT, Derewenda ZS (2012) Biochemistry 51(33): 6499-510
   › Primary publication · 22846040 (PubMed) · PMC3462495 (PubMed Central)
5. Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability. Hilinski MK, Mrozowski RM, Clark DE, Lannigan DA (2012) Bioorg Med Chem Lett 22(9): 3244-7
   › Primary publication · 22464132 (PubMed) · PMC3331937 (PubMed Central)
6. Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue. Pasic L, Eisinger-Mathason TS, Velayudhan BT, Moskaluk CA, Brenin DR, Macara IG, Lannigan DA (2011) Genes Dev 25(15): 1641-53
   › Primary publication · 21828273 (PubMed) · PMC3182019 (PubMed Central)
7. Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors. Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Lannigan D, Smith J, Scudiero D, Kondapaka S, Shoemaker RH (2011) Eur J Med Chem 46(9): 4311-23
   › Primary publication · 21794960 (PubMed)
8. RSK2 Binding Models Delineate Key Features for Activity. Gussio R, Currens MJ, Scudiero DA, Smith JA, Lannigan DA, Shoemaker RH, Zaharevitz DW, Nguyen TL (2010) J Chem Pharm Res 2(5): 587-598
   › Primary publication · 21593990 (PubMed) · PMC3094916 (PubMed Central)
9. A chromatin-bound kinase, ERK8, protects genomic integrity by inhibiting HDM2-mediated degradation of the DNA clamp PCNA. Groehler AL, Lannigan DA (2010) J Cell Biol 190(4): 575-86
   › Primary publication · 20733054 (PubMed) · PMC2928013 (PubMed Central)
10. RSK in tumorigenesis: connections to steroid signaling. Eisinger-Mathason TS, Andrade J, Lannigan DA (2010) Steroids 75(3): 191-202
    › Primary publication · 20045011 (PubMed) · PMC2823981 (PubMed Central)
11. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM (2009) Proc Natl Acad Sci U S A 106(23): 9268-73
    › Primary publication · 19470470 (PubMed) · PMC2695095 (PubMed Central)
12. Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival. Eisinger-Mathason TS, Andrade J, Groehler AL, Clark DE, Muratore-Schroeder TL, Pasic L, Smith JA, Shabanowitz J, Hunt DF, Macara IG, Lannigan DA (2008) Mol Cell 31(5): 722-36
    › Primary publication · 18775331 (PubMed) · PMC2654589 (PubMed Central)
13. RNA suppression of ERK2 leads to collapse of mitochondrial membrane potential with acute oxidative stress in human lens epithelial cells. Flynn JM, Lannigan DA, Clark DE, Garner MH, Cammarata PR (2008) Am J Physiol Endocrinol Metab 294(3): E589-99
    › Primary publication · 18171912 (PubMed)
14. Structural basis for the activity of the RSK-specific inhibitor, SL0101. Smith JA, Maloney DJ, Hecht SM, Lannigan DA (2007) Bioorg Med Chem 15(14): 5018-34
    › Primary publication · 17512736 (PubMed)
15. Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. Nguyen TL, Gussio R, Smith JA, Lannigan DA, Hecht SM, Scudiero DA, Shoemaker RH, Zaharevitz DW (2006) Bioorg Med Chem 14(17): 6097-105
    › Primary publication · 16723234 (PubMed)
16. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK. Smith JA, Maloney DJ, Clark DE, Xu Y, Hecht SM, Lannigan DA (2006) Bioorg Med Chem 14(17): 6034-42
    › Primary publication · 16723233 (PubMed)
17. Three acetylated flavonol glycosides from Forsteronia refracta that specifically inhibit p90 RSK. Xu YM, Smith JA, Lannigan DA, Hecht SM (2006) Bioorg Med Chem 14(11): 3974-7
    › Primary publication · 16524738 (PubMed)
18. Novel biosensors for the detection of estrogen receptor ligands. De S, Macara IG, Lannigan DA (2005) J Steroid Biochem Mol Biol 96(3-4): 235-44
    › Primary publication · 15985367 (PubMed)
19. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Clark DE, Errington TM, Smith JA, Frierson HF, Weber MJ, Lannigan DA (2005) Cancer Res 65(8): 3108-16
    › Primary publication · 15833840 (PubMed)
20. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA (2005) Cancer Res 65(3): 1027-34
    › Primary publication · 15705904 (PubMed)
21. Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Henrich LM, Smith JA, Kitt D, Errington TM, Nguyen B, Traish AM, Lannigan DA (2003) Mol Cell Biol 23(17): 5979-88
    › Primary publication · 12917323 (PubMed) · PMC180983 (PubMed Central)
22. Estrogen receptor phosphorylation. Lannigan DA (2003) Steroids 68(1): 1-9
    › Primary publication · 12475718 (PubMed)
23. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA (2001) EMBO J 20(13): 3484-94
    › Primary publication · 11432835 (PubMed) · PMC125527 (PubMed Central)
24. Creation of a stress-activated p90 ribosomal S6 kinase. The carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal transduction pathway in which they function. Smith JA, Poteet-Smith CE, Lannigan DA, Freed TA, Zoltoski AJ, Sturgill TW (2000) J Biol Chem 275(41): 31588-93
    › Primary publication · 10922375 (PubMed)
25. Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family. Poteet-Smith CE, Smith JA, Lannigan DA, Freed TA, Sturgill TW (1999) J Biol Chem 274(32): 22135-8
    › Primary publication · 10428774 (PubMed)
26. The function of the p190 Rho GTPase-activating protein is controlled by its N-terminal GTP binding domain. Tatsis N, Lannigan DA, Macara IG (1998) J Biol Chem 273(51): 34631-8
    › Primary publication · 9852136 (PubMed)
27. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. Joel PB, Traish AM, Lannigan DA (1998) J Biol Chem 273(21): 13317-23
    › Primary publication · 9582378 (PubMed)
28. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA (1998) Mol Cell Biol 18(4): 1978-84
    › Primary publication · 9528769 (PubMed) · PMC121427 (PubMed Central)
29. Use of the yeast one-hybrid system to screen for mutations in the ligand-binding domain of the estrogen receptor. Bush SM, Folta S, Lannigan DA (1996) Steroids 61(3): 102-9
    › Primary publication · 8852826 (PubMed)
30. Analysis of estrogen receptor interaction with tertiary-structured estrogen responsive elements. Lannigan DA, Tomashek JJ, Obourn JD, Notides AC (1993) Biochem Pharmacol 45(9): 1921-8
    › Primary publication · 8494551 (PubMed)
31. Estrogen-responsive elements contain non-B DNA. Lannigan DA, Koszewski NJ, Notides AC (1993) Mol Cell Endocrinol 94(1): 47-54
    › Primary publication · 8375575 (PubMed)
32. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Joel PB, Traish AM, Lannigan DA (1995) Mol Endocrinol 9(8): 1041-52
    › Primary publication · 7476978 (PubMed)
33. Decreased intracellular Na+ concentration is an early event in murine erythroleukemic cell differentiation. Lannigan DA, Knauf PA (1985) J Biol Chem 260(12): 7322-4
    › Primary publication · 3858279 (PubMed)
34. Relationship of the decreases in protein synthesis and intracellular Na+ during friend murine erythroleukemic cell differentiation. Lannigan DA, Knauf PA, Macara IG (1986) J Biol Chem 261(31): 14430-6
    › Primary publication · 3464599 (PubMed)
35. Phenamil, an amiloride analogue, inhibits differentiation of Friend murine erythroleukemic cells. Lannigan DA, Bennington JB, Cragoe EJ, Knauf PA (1988) Am J Physiol 254(1 Pt 1): C122-9
    › Primary publication · 3422134 (PubMed)
36. Estrogen receptor selectively binds the "coding strand" of an estrogen responsive element. Lannigan DA, Notides AC (1989) Proc Natl Acad Sci U S A 86(3): 863-7
    › Primary publication · 2915982 (PubMed) · PMC286578 (PubMed Central)
37. Estrogen regulation of transcription. Lannigan DA, Notides AC (1990) Prog Clin Biol Res : 187-97
    › Primary publication · 2406732 (PubMed)
38. A novel mechanism for eukaryotic gene expression. The involvement of DNA tertiary structure in estrogen receptor recognition of its target nucleotide sequence. Lannigan DA, Notides AC (1990) Biochem Pharmacol 40(12): 2579-85
    › Primary publication · 2260983 (PubMed)

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword